| Trial ID: | L1588 |
| Source ID: | NCT00807144
|
| Associated Drug: |
Tacrolimus (Kidney Transplant Maintenance Immunosuppression)
|
| Title: |
Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation
|
| Acronym: |
TAESR
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00807144/results
|
| Conditions: |
End-stage Renal Failure|Graft Rejection
|
| Interventions: |
DRUG: Tacrolimus (Kidney transplant maintenance immunosuppression)|DRUG: Kidney transplant maintenance immunosuppression
|
| Outcome Measures: |
Primary: Patient Survival With a Functioning Graft, One year post kidney transplantation | Secondary: Rejection-free Patient Survival With a Functioning Graft, One and two years post kidney transplantation|Patient-reported Quality of Life, and Medication Adherence, 3,6,& 12 months post kidney transplant
|
| Sponsor/Collaborators: |
Sponsor: Imperial College Healthcare NHS Trust
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
102
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2008-12
|
| Completion Date: |
2012-03
|
| Results First Posted: |
2021-08-27
|
| Last Update Posted: |
2021-08-27
|
| Locations: |
West London Renal & Transplant Centre, Hammersmith Hospital, London, W12 0HS, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT00807144
|
